Synergistic effect resulting from combinations of a bifunctional HIV-1 antagonist with antiretroviral drugs

Journal of Acquired Immune Deficiency Syndromes

Volumn 67, Issue 1, 2014, Pages 1-6

  Xu, Wei ^a   Wang, Qian ^a   Yu, Fei ^a   Lu, Lu ^a   Jiang, Shibo ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NEW YORK BLOOD CENTER   (United States)

Author keywords

combination; drug resistance; HAART; HIV entry inhibitor; synergism

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DAPIVIRINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLERIXAFOR; PROTEIN 2DLT; RECOMBINANT PROTEIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG POTENTIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; PRIORITY JOURNAL; SALVAGE THERAPY; VIRUS STRAIN; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; HIV INFECTIONS; IC50; VIROLOGY;

ANTI-HIV AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84906077257     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000265     Document Type: Article

References (16)

1. Louie M, Hogan C, Di Mascio M, et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis. 2003;187:896-900.
2. De Clercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov. 2007;6:1001-1018.
3. Jiang S, Lin K, Strick N, et al. HIV-1 inhibition by a peptide. Nature. 1993;365:113.
4. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA. 1994;91:9770-9774.
5. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
6. Liu S, Jing W, Cheung B, et al. HIV gp41 C-terminal heptad repeat contains multifunctional domains: relation to mechanisms of action of anti-HIV peptides. J Biol Chem. 2007;282:9612-9620.
7. Lu J, Deeks SG, Hoh R, et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis. J Acquir Immune Defic Syndr. 2006;43:60-64.
8. Delmedico M, Bray B, Cammack N, et al. Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006.
9. Dwyer JJ, Wilson KL, Davison DK, et al. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA. 2007;104:12772-12777.
10. Lu L, Pan C, Li Y, et al. A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology. 2012;9:104.
11. Jiang S, Lu H, Liu S, et al. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother. 2004;48:4349-4359.
12. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
13. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58:621-681.
14. Larder BA, Kellam P, Kemp SD. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 1993;365:451-453.
15. Mo H, Konstantinidis AK, Stewart KD, et al. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology. 2004;329:319-327.
16. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfu-virtide. J Infect Dis. 2003;188:1827-1833.